References
- Behcet H. Uber rezidivierende aphtose, durch em n virus verur-sachte Geschwure am Mund, am Auge und an den Genitalien. Dermatol Wochenschr 1937;105:1152–7.
- Lakhanpal S, Tam K, Lie if, Katoh K, Ishigatsubo Y, Ohokubo T. Pathologic features of Behçet's syndrome: a review of Japanese autopsy registry data. Hum Pathol 1985;16:790–7999.
- International Study Group for Behçet's Disease. Criteria for diag-nosis of Behçet's disease. Lancet 1990;335:1078–80.
- Pines A, Kaplinsky N, Olchovsky D, Bregman J, Frankl O. Fever of undetermined origin as the presenting symptom of Behçet's disease: A favorable response to colchicine. South Med J 1984;77: 802–3.
- Gotfried M, Jutrin H, Ravid M, Sava K. Behçet's disease preceded by fever of unknown origin. Arch Intern Med 1985;145:1329.
- Robert M, Harper MP. Use of colchicine in the treatment of Behçet's disease. Int J Dermatol 1982;21:551–4.
- Matsmura N, Mizushima Y. Leukocyte movement and colchicine treatment of Behçet's disease. Lancet 1975;2:813.
- Diindar S, Ozcebe 01, Ozdemir O. Alpha interferon in the treat-ment of Behçet's disease. Rev Med Int 1993;14:49.
- Azizlerli G, Sarica R, Köse A, Ovill C, Kavala M, Kayabah M, et al. Interferon alfa-2a in the treatment of Behçet's disease. Derma-tology 1996;192: 239–41.
- Tsambaos D, Eichelberg D, Goos M. Behçet's syndrome: treat-ment with recombinant leukocyte alpha-interferon. Arch Dermatol Res 1986;278:335–6.
- Sayek I, Aran O, Uzunalimoglu B, Hersek E. Intestinal Behçet's disease: surgical experience in seven cases. Hepatogastro-enterology 1991;81:81–3.
- Hamza MH. Cancer complicating Behçet's disease treated with chlorambucil. Ann Rheum Dis 1986;45:789.
- Celik I, Altundag K, Erman M, Baltah E. Cyclophosphamide-associated carcinoma of the urinary bladder in Behçet's disease. Nephron 1998;81:239.
- Diindar S, Timtek H, Ruacan T. Behçet's disease and malignancy. Ann Chin Res 1984;6:55–9.
- Oto A, Oktay A, Diindar S, Arioglu S, SOzen T, Sandikci S, et al. Behçet's disease. Tiirkiye Klin Tip Bilim Arast Derg 1985;3:14–20.